Chairs

Cheryl Ho, MD, FRCP(C)

Clinical Assistant Professor of Medicine, UBC
Medical Oncologist, BC Cancer
Vancouver, BC

Cheryl Ho is a clinical assistant professor at the University of British Columbia and a medical oncologist at  British Columbia Cancer.

She is currently the provincial systemic chair for head and neck malignancies.

She completed medical school and internal medicine training at the University of Western Ontario.

She is a graduate of the BC Cancer Agency Medical Oncology program and completed a fellowship in Thoracic Oncology at University of California, Davis.

Her current practice focuses on the treatment of thoracic and head and neck malignancies.

Barbara Melosky, MD, FRCP(C)

Professor of Medicine, UBC
Medical Oncologist, BC Cancer
Vancouver, BC

Dr. Melosky is a Professor of Medicine at the University of British Columbia and a Medical Oncologist at the British Columbia Cancer Agency.
She graduated from medical school at the University of Manitoba and did a residency in internal medicine at the University of British Columbia.

She is currently a medical oncologist at  BC Cancer  with clinical interests in GI and respiratory malignancies.

She is also the chairperson of the Colorectal Screening Program of British Columbia and has a special interest in EGFR receptors and management of side effects.

Randeep Sangha, MD, FRCPC

Medical Oncologist, Cross Cancer Institute
Assistant Professor, University of Alberta
Edmonton, AB

Dr. Sangha is an Associate Professor in the Department of Oncology at the University of Alberta and Medical Oncologist at the Cross Cancer Institute, Edmonton, AB. He is the Provincial Lead for the Alberta Lung Cancer Program.

Dr. Sangha received his medical degree at the University of Alberta and subsequently specialized in Internal Medicine and Medical Oncology. He completed two years of post-fellowship training in thoracic oncology at the University of California, Davis Comprehensive Cancer Center.

His academic, clinical, and educational activities revolve around thoracic and hematological malignancies. He is also experienced in Investigational New Drug (Phase I) development and is actively involved in the Phase I clinical trials program at the Cross Cancer Institute.

Faculty

Penelope Bradbury, MB, BCh, FRACP, MD (UK)

Associate Professor, Department of Medicine, University of Toronto
Associate Professor, Department of Oncology, Queen’s University
Medical oncologist, Princess Margaret Cancer Centre
Toronto, ON

Penelope Bradbury is a staff medical oncologist at the Princess Margaret Cancer Centre, Toronto, Canada; Associate Professor, Department of Medicine, University of Toronto, and adjunct Associate Professor within the Department of Oncology at Queen’s University, Kingston, Canada. She has a research interest in the evaluation of new therapies for the management of thoracic malignancies and clinical trial methodology and is the current chair of the Canadian Cancer Trials Group Thoracic Disease Site Committee.

Dr Chasen was the Regional Palliative care physician lead for Palliative Care- Champlain LHIN from 2009-2015 and is presently the Medical co-lead for the Palliative Care Network in the Central West LHIN.

Rebecca Brown, MSW, RSW, CCC

Rebecca Brown has a Masters Degree in Social Work and her career has spanned 30 years within medical social work, child welfare and domestic violence.  The majority of her career was in the child protection system as a Supervisor and Coordinator of the Critical Incident Debriefing Team.  She was a Provincial Trainer for the Ont. Association of Children’s Aid Societies and taught the curriculum on Wellness and Self-Care.  Her experience in resilience building and Lifestyle Medicine is incorporated into her practice of Health & Wellness Coaching.  Rebecca is an Assistant Professor in the Department of Family Medicine, Western University and Associate with the TEND Academy delivering workshops and conferences throughout Canada and the US on the topics of Vicarious Trauma, Compassion Fatigue and Resilience to professionals in the trauma and health fields. Rebecca’s most recent passion is “Healing Through Horses” and practices Equine Assisted Therapy for trauma survivors.

Dr Chasen was the Regional Palliative care physician lead for Palliative Care- Champlain LHIN from 2009-2015 and is presently the Medical co-lead for the Palliative Care Network in the Central West LHIN.

Martin Robert Chasen, MBChB, FCP(SA), MPhil(Pall Med)

Associate Professor, Division of Palliative Care, University of Ottawa
Medical Director, Palliative Care,
William Osler Health System
Medical Director, Palliative Rehabilitation, Élisabeth Bruyère Hospital
Brampton, ON

Dr. Martin Chasen is currently the Medical Director of Palliative Care, at William Osler Health System in Brampton. He was previously Medical Director, Palliative Care, at The Ottawa Hospital Cancer Centre and the Palliative Rehabilitation Program at Élisabeth Bruyère Hospital, Ottawa.

Dr. Chasen, born in Pretoria, South Africa completed his undergraduate training in medicine and surgery at the University of Pretoria in 1983, later obtaining a specialist degree in Internal Medicine and Medical Oncology and Master of Philosophy (Palliative Medicine) at the University of Cape Town, South Africa. He is a founding member of the palliative care working group European Society of Medical Oncology and faculty member of ESMO education. In 2009, Dr. Chasen, was Team Leader and Physician, Cancer Nutrition & Rehabilitation Program at McGill University Hospital Complex obtained “Supra regionale de niveau 3” status for the PQCCC.  In 2013, Dr. Chasen and the team at Ottawa Hospital cancer centre achieved ESMO Designated Centre of Integrated Oncology and Palliative care.

He currently holds professorships at the Universities of Toronto, McMaster, Ottawa and McGill. He recently received the Elizabeth J Latimer Prize in Palliative Care from Mc Master University.

He has in excess of 100 peer reviewed publications, abstracts and book chapters. Dr. Chasen is the principle investigator of CIHR (Canadian Institutes of Health Research). This MENAC (The Multimodal Exercise/Nutrition/Anti-inflammatory treatment for Cachexia), trial will investigate the addition of the multimodal intervention for patients receiving standard chemotherapy for metastatic cancer. He was also one of the chief investigators for the initial clinical trials on the use of Rolapitant-a novel NKI inhibitor in the treatment of chemo therapy induced nausea and vomiting.

Dr. Chasen has lectured nationally and internationally on rehabilitation of patients with cancer, approaches to treatment of patients with cachexia, chemotherapy induced nausea and vomiting, survivorship and symptom relief.

Dr Chasen was the Regional Palliative care physician lead for Palliative Care- Champlain LHIN from 2009-2015 and is presently the Medical co-lead for the Palliative Care Network in the Central West LHIN.

Marcelo Cypel MD, MSc, FRCSC

Canada Research Chair in Lung Transplantation (Tier 2)
Surgical Director ECLS Program UHN
Thoracic Surgeon, University Health Network
Associate Professor of Surgery
Division of Thoracic Surgery
University of Toronto
Toronto, ON

Dr. Cypel is a Staff Thoracic Surgeon at University Health Network (UHN) and an Associate Professor of Surgery at the University of Toronto. He is the Surgical Director of the Artificial Lung Program at UHN.  He received his MD in 1999 and completed his general surgery and thoracic surgery residency program in 2004. In 2005 he started his post-doctoral research fellowship at the Latner Thoracic Surgery Laboratory. During this time, he developed a new method of lung preservation and donor lung repair called Ex Vivo Lung Perfusion (EVLP). This method is now used clinically in Toronto and in many other centers, and has significantly increased the number of transplantable lungs.  He subsequently performed a 3 years fellowship in thoracic oncology, cardiac surgery, and lung transplantation at the University of Toronto. During his training, he has received 13 awards, including the McMurrich Award given for the best fundamental science work by any level trainee in the Department of Surgery and the 1st Annual Zane Cohen Clinical Fellowship Achievement Award from the Canadian Society of Transplantation. He also achieved a large number of 1st and senior author peer review publications including high impact journals such as Science Translational Medicine, The New England Journal of Medicine and The Lancet. His main clinical interests are in artificial lung devices, Ex vivo and In vivo Lung Perfusion and lung transplantation. He has secured over 2 million in peer review funding over the last 5 years including CIHR grants. His international leadership is also evident by chairing the DCD registry within the International Society of Heart and Lung Transplantation.  Dr. Cypel currently holds the prestigious Canada Research Chair in Lung Transplantation from the Government of Canada and he is the principal investigator in very innovative clinical trials, such as the use of uncontrolled donation after cardio-circulatory death for lung transplantation and in vivo lung perfusion with chemotherapy to treat patients with lung metastases. He is a Member of the American Association for Thoracic Surgery (AATS) and a Fellow from the Royal College of Physicians and Surgeons of Canada (FRCSC).  His list of publications can be found at: https://www.ncbi.nlm.nih.gov/pubmed/?term=cypel%2Cmarcelo

Parneet K. Cheema, MD, MBiotech, FRCPC

Assistant Professor, Department of Medicine
University of Toronto
Medical Oncologist, William Osler Health System
Toronto, ON

Dr. Cheema is an Assistant Professor in the Department of Medicine at the University of Toronto, with a focus on quality improvement. She is a medical oncologist who started her career at Sunnybrook Health Sciences Centre and then moved to William Osler Health System in Brampton/Toronto where she is the lead for lung cancer and clinical trials. She completed her medical oncology training at the University of Toronto, and completed a professional Master of Biotechnology degree from the University of Toronto that integrated the business and science of drug development.  She has been an investigator for numerous immunotherapy and targeted therapy lung cancer clinical trials and has participated as a steering committee member on global trials. Her research interests include the implementation of advances of lung cancer and immunotherapy into day to day practice. Since her time at William Osler Health System she has developed the novel concept of an immunotherapy for cancer clinic. She is the immunotherapy section editor for the Canadian oncology journal Current Oncology. She is also involved in health technology assessment, having been a voting member for the Ontario Steering Committee for Cancer drugs and is currently a clinical reviewer for PCODR.

Dr. David Dawe

Assistant Professor, University of Manitoba
Medical Oncologist, CancerCare Manitoba
Winnipeg, MB

Dr. Dawe is a medical oncologist at CancerCare Manitoba and assistant professor at the University of Manitoba. In addition to his MD and FRCPC, he completed a Geriatric Thoracic Oncology Fellowship at the Juravinski Cancer Centre and an MSc at the University of Manitoba. He currently holds the Manitoba Medical Service Foundation John Henson Clinical Research Professorship in Population Health. Dr. Dawe is currently examining patterns of care for lung cancer patients and for older patients with cancer to identify opportunities for system improvement and knowledge translation.

Peter Ellis MBBS MMed(Clin Epi) PhD FRACP FRCPC

Professor, Departments of Oncology and Clinical Epidemiology & Biostatistics
McMaster University
Division Head of Medical Oncology, Juravinski Cancer Centre
Montreal, QC

Dr. Ellis is a Professor in the Departments of Oncology and Clinical Epidemiology & Biostatistics at McMaster University.  He is also Division Head of Medical Oncology at the Juravinski Cancer Centre (JCC).  He obtained his medical degree at the University of Sydney. He completed a Masters of Medicine (Clinical Epidemiology) and a PhD also at the University of Sydney.  Dr Ellis moved to Canada in October, 2000.  He is an Executive Member of the Canadian Cancer Trials Group (CCTG) Lung Disease Site Committee, and is Co-Chair of Cancer Care Ontario’s Practice Guideline Initiative, Provincial Lung Disease Site Group.  He is also an investigator on several NCIC and pharmaceutical industry-sponsored multicentre phase III clinical trials in breast and lung cancer. 

David R. Gandara, MD

Professor of Medicine Emeritus
University of California at Davis, School of Medicine
Director, Thoracic Oncology Program
UC Davis Comprehensive Cancer Center
Davis, CA

David R. Gandara, MD, Professor of Medicine Emeritus at the University of California at Davis (UC Davis) School of Medicine is the Senior Advisor to the Director, and Director of the Thoracic Oncology Program at UC Davis Comprehensive Cancer Center (UCDCCC).  He is an internationally known clinician-scientist and lung cancer thought leader. He has led many notable research projects in lung cancer, including early therapeutics trials at various phases, cooperative group trial through the Southwest Oncology Group (SWOG), and translational science projects.  He is the clinical director for a National Cancer Institute (NCI) award to the California Cancer Consortium for Early Therapeutic Trials of New Anti-Cancer Agents. He is past chair of the Southwest Oncology Group (SWOG) Lung Committee, and a member and founding co-chair of the NCI-directed Investigational Drug Steering Committee (IDSC). He has written over 700 articles, book chapters, abstracts and editorials. He is Editor-in-chief of the journal Clinical Lung Cancer. He served as president of the International Association for the Study of Lung Cancer (IASLC) from 2009-2011 and served as treasurer from 2013-2017. He is a prior board member and secretary-treasurer of the American Society for Clinical Oncology (ASCO). Most recently, he serves as Clinical Director for the joint Jackson Laboratory (JAX)-UCDCCC patient-derived xenotransplant (PDX) program in lung cancer, and is UCD Comprehensive Cancer Center’s principal investigator for the Stand Up To Cancer (SU2C) dream team in KRAS-mutated lung cancer.

Daniel Gomez, MD

Head, Thoracic Radiation Oncology
MD Anderson
Texas, USA

Dr. Gomez received his BA in economics at the University of Virginia, followed by his medical degree (MD) at the University of California, San Francisco. He then completed his residency training in radiation oncology at Memorial Sloan-KetteringCancer Center. Dr. Gomez joined MD Anderson in 2009 and he currently serves as the thoracic radiation oncology section head. His research focuses on mesothelioma, radiation toxicity, and lung cancer with limited sites of disease spread, termed “oligometastatic” non-small cell lung cancer (NSCLC). He has completed several clinical trials on these topics, including the first randomized study demonstrating a benefit with aggressive treatment (surgery or radiation) in patients that have oligometastatic NSCLC. He continues to develop multiple phase II and phase III studies and lead translational research efforts related to these clinical interests.

Kyle Grant, MD, MHSc, FRCSC

Clinical Instructor, Division of Thoracic Surgery
University of British Columbia
Vancouver, BC

Dr. Kyle Grant is a Thoracic Surgeon at Vancouver General Hospital.  He completed his medical school training and General Surgery residency at the University of Manitoba.  He subsequently completed his Thoracic Surgery Fellowship at the University of British Columbia and also holds a Masters Degree from the School of Population and Public Health at UBC.  His interests are Thoracic Oncology and Minimally Invasive Thoracic Surgery.

Waël Hanna MDCM, MBA, FRCSC

Assistant Professor, Department of Surgery
Division of Threoracic Surgery, McMaster University
Scientist, Research Institute of St. Joseph’s Healthcare Hamilton
Thoracic Surgeon, St. Joseph’s Healthcare Hamilton
Hamilton, ON

Dr. Waël Hanna has been practicing surgery in Canada since 2001. He completed medical school at McGill University in 2005 and continued his General Surgery residency there until 2011. In 2013, Dr. Hanna completed a fellowship in Thoracic Surgery at the University of Toronto and joined the Division of Thoracic Surgery at McMaster University. In addition to his medical training, Dr. Hanna is also a graduate of Hautes Etudes Commerciales (HEC-Montreal) where he earned his Masters of Business Administration in 2008.

He also holds several hospital appointments within the Brant Community Health System, Niagara Health System, Juravinski Cancer Centre, Hamilton Health Sciences, and St. Joseph’s Healthcare.

Recently, Dr. Hanna has gained media attention for his work in the field of robotic thoracic surgery. These minimally invasive procedures are enabling his patients to recover more quickly and comfortably. On top of his roles as thoracic surgeon and medical researcher, Dr. Hanna is also a passionate advocate for each of his patients.

Dr. David Hong

Deputy Chair, Department of Investigational Cancer Therapeutics
Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Houston, TX

Dr. Hong joined University of Texas MD Anderson in 2005. He received his MD from Albert Einstein College of Medicine, Yeshiva University, in the Bronx, New York and served as an intern and resident at Thomas Jefferson University in Philadelphia.

Dr. Hong completed a fellowship in medical oncology at MD Anderson, where he was appointed Chief Medical Oncology Fellow. His research interests include phase I studies, drug development, the molecular basis for cancer clinical interest therapy, biologic molecules, and novel protocol designs. Dr. Hong has received numerous awards including the Amgen Young Investigator Award, the Jesse H. Jones Award and the Goodwin Funding Award.

Rosalyn Juergens, B.S. (Hons), MD., PhD

Associate Professor, Department of Oncology
McMaster University
Adjunct Assistant Professor, Department of Oncology
The Johns Hopkins Medical Institute
Hamilton, ON

Dr. Juergens received her medical degree from Georgetown University in Washington, D.C.  She was an intern and resident in the Osler Internal Medicine Training Program at The Johns Hopkins Medical Institute. She completed a fellowship in medical oncology with a focus on upper aerodigestive malignancies as well at Johns Hopkins.  Additionally, she completed her Ph.D. in Clinical Investigation at The Johns Hopkins Bloomberg School of Public Health. She was on the faculty at Johns Hopkins from 2007-2010 until she joined the faculty at McMaster University in 2011. 

Dr. Juergens’ chairs the Lung Disease Site Team at the Juravinski Cancer Centre in Hamilton, Ontario.  She is a member of the Escarpment Cancer Research Institute.  She is the Head of the Department of Clinical Trials at the Juravinski Cancer Centre.  She is the incoming chair for the Investigational New Drug Committee at the Canadian Cancer Trials Group.   She is also a patient advocate and serves as the Medical Advisory Committee Chair for Lung Cancer Canada. 

She enjoys singing, playing board and card games, hosting parties, and baking crazy birthday cakes as only a woman plagued with mommy guilt can do.  She keeps these other skills refined in case this debate against Dr. Shepherd crushes her lung cancer career. 

Stephen Lam, MD, FRCPC

Professor of Medicine, Respiratory Division, UBC
Chair, Lung Tumour Group, BC Cancer
Vancouver, BC

Dr. Lam is Professor of Medicine at UBC in the Respiratory Division. He is currently Chair of the Lung Tumour Group and directs the MDS-Rix Early Lung Cancer Detection and Translational Research Program at  BC Cancer . He is a Distinguished Scientist in the Department of Integrative Oncology at the BC Cancer Research Centre. Dr. Lam’s research interest is in early detection, chemo prevention, endoscopic diagnosis and treatment of lung cancer. He was the recipient of the Joseph Cullen Award for life – time scientific achievements in lung cancer prevention research by the International Association for the Study of Lung Cancer and the UBC Killam Award.

Dr. Geoffrey Liu

Thoracic Medical Oncologist
Molecular Pharmacoepidemiologist
Clinician Scientist
Princess Margaret Cancer Centre
Toronto, ON

Geoffrey Liu is a thoracic medical oncologist, a molecular pharmacoepidemiologist, and clinician scientist from Princess Margaret Cancer Centre. Besides drooling about ALK and other rare molecular alterations in lung cancer, Dr. Liu loves his flower gardens and sending emails to people in the middle of the night.

Leslie Markin, RN

Interventional Respirologist, BC Cancer
Vancouver, BC

Leslie Markin is a Clinical Trials Nurse Coordinator for the Lung Tumor Group at BC Cancer in Vancouver, Canada. She graduated from University of Alberta Hospital School of Nursing and previously worked in ER and Ambulatory Care Chemotherapy Unit.

Ms. Katherine McKay

Health Promoter, QuitNow
Government of BC

Katherine McKay is a health promoter for QuitNow, a free quit-smoking program of the Government of BC.  She works in the community in a variety of ways, such as attending health fairs and community events, training healthcare professionals, and meeting with like-minded organizations.

Renelle Myers MD, FRCPC

Clinical Trials Nurse Coordinator, BC Cancer
Vancouver, BC

Renelle Myers is an interventional respirologist at BCCA.  She completed internal medicine and respirology training at the University of Manitoba and Interventional Pulmonary training at Beth Deaconess Center, Harvard University.  She is also cross appointed between respirology and thoracic surgery at Vancouver general hospital.

She is a member of the Canadian Partnership Against Cancer tobacco cessation network and the program lead for the implementation of smoking cessation at BCCA.  

Dr. David Palma

Radiation Oncologist, London Health Sciences Centre
Clinician-Scientist, Ontario Institute for Cancer Research
London, ON

Dr. David Palma is a radiation oncologist at the London Health Sciences Centre and a Clinician-Scientist with the Ontario Institute for Cancer Research.  He holds an MD from the University of Western Ontario, a Master’s Degree in Epidemiology from the Harvard School of Public Health, and a PhD from the VU University in Amsterdam. He completed his residency in Radiation Oncology in Vancouver, Canada. He is the chair of the Canadian Pulmonary Radiotherapy Investigators (CAPRI) group, and the author of the bestselling book Taking Charge of Cancer: What You Need to Know to Get the Best Treatment.

Rizwan Qureshi, MD

Clinical Associate, Tom Baker Centre
CEO, Kannavolve Group
Calgary, AB

Dr. Qureshi, Md is the CEO of Kannavolve group. Born and raised in Calgary, Alberta completed his Family Medicine Residency and Fellowship in Family Oncology at the University of Manitoba. Currently he works as a clinical associate at Tom Baker Centre with Alberta Health Services and various specialty clinics. He is dedicated to education and research in the field of medical cannabis. Dr. Qureshi is interested in establishing safe practice recommendations for medical cannabis use, and to enhance medical cannabis knowledge for healthcare providers, patients, and the general public.

Jeffrey Rothenstein, MD FRCPC

Medical Oncologist
R.S. McLaughlin Durham Regional Cancer Center
Adjunct Assistant Professor, Queen’s University
Kingston, ON

Dr. Jeff Rothenstein is a medical oncologist at the R.S. McLaughlin Durham Regional Cancer Center in Oshawa and is an adjunct assistant professor in the Department of Oncology at Queen’s University.

He completed his internal medicine and medical oncology training at the University of Toronto.

His main clinical focus is on the management of thoracic and GI malignancies. He is the lung cancer site group and clinical trial group leader at the R.S. McLaughlin Durham Regional Cancer Center.

Dr. Benoit Samson

Professor, Clinical Hematology & Medical Oncology
Medical Director, Clinical Laboratory Network
Hematologist & Medical Oncologist
Monteregie Cancer Centre, Charles-LeMoyne Hospital
Longueuil, QC

Benoit Samson is Hematologist and Medical Oncologist and professor of clinical hematology and medical oncology at the Monteregie Cancer Centre, Charles-LeMoyne Hospital. He is now the medical director of clinical laboratory network. 

He received his medical degres from the University of Sherbrooke and he completed his training in Internal Medecine and Hematology at Laval University,  Quebec city. Dr Samson did a fellowship in Medical Oncology at the University of British Columbia, Vancouver Cancer Clinic.

Dr. Samson’s major clinical and research interest are in gastrointestinal  and lung cancer. He has been involved as principal investigator of phase II and III clinical trial.

Devin Schellenberg, MD, FRCS(C)

Clinical Instructor, Radiation Oncologist
Department of Radiation Oncology
BC Cancer , Abbotsford Centre & Fraser Valley Centre
Vancouver, BC

Dr. Devin Schellenberg is a radiation oncologist practicing in the Fraser Valley and Abbotsford Cancer Centres. He is currently the head of the Clinical Trials Unit at the Abbotsford Cancer Centre and is one of the leaders in the British Columbia stereotactic radiation working group.

His radiation oncology residency was carried out at Princess Margaret Hospital in Toronto and the BC Cancer Agency, after which he completed a fellowship in stereotactic body radiation therapy at Stanford University in 2007.

His present research is focused on the use of novel imaging modalities in radiation therapy.

Brandon Sheffield MD FRCPC

Anatomic Pathologist
Medical Director of Immunohistochemistry
William Osler Health System
Brampton, ON

Dr. Brandon Sheffield is an anatomic pathologist with the William Osler Health System in Brampton, Ontario.  He is currently serving as the laboratory’s medical director of immunohistochemistry.  

Dr. Sheffield studied genetics in London and Toronto before starting his medical training at the University of Toronto.  He completed his residency training at the University of British Columbia, with a focus towards molecular genetic pathology, and personalized medicine. 

Dr. Sheffield’s main focus is around developing molecular testing programs that can be readily utilized in community cancer care settings.     

Frances A. Shepherd, OC, OOnt, MD, FRCPC, LLD (Hon)

Professor of Medicine, University of Toronto
Senior Staff Physician
Princess Margaret Cancer Centre
Toronto, ON

Dr. Shepherd received her medical degree from the University of Toronto, Ontario, Canada and is currently a Senior Staff Physician at Princess Margaret Cancer Centre in Toronto, where she holds the Scott Taylor Chair in Lung Cancer Research. She is a Full Professor of Medicine at the University of Toronto and served as the University Division Director for Medical Oncology from 1997 to 2003.

Dr. Shepherd has been recognised for her many contributions in the field of lung cancer research, most notably her long-standing international leadership in the development of innovative therapies for this indication. In 2001, she was named the Scott Taylor Chair in Lung Cancer Research, becoming the first holder of this esteemed research position with a primary goal of investigating new treatments for lung cancer. Dr Shepherd served as Chair of the Lung Cancer Committee of the National Cancer Institute of Canada Clinical Trials Group for 19 years and was President of International Association for the Study of Lung Cancer (IASLC) from 2003 to 2005. She has been a member of the Board of Directors of the American Society of Clinical Oncology (ASCO) and of the European Organisation for Research and Treatment of Cancer (EORTC). She Chaired the EORTC Protocol Review Committee for 10 years until 2018. Dr Shepherd also served as Chair of the ASCO Membership and Publications Committees. She was the recipient of the Jacqueline Seroussi Memorial Foundation for Cancer Research Award from Israel in 2004; the National Cancer Institute of Canada O. Harold Warwick Award for Research Excellence in 2006; the IASLC Research Award in 2007; the Ontario Premier’s Summit Award for Research in 2009; and a Boehringer-Ingelheim Innovation Award in 2010. In recognition of her contributions to cancer research and treatment, she received the Order of Ontario in 2007. In 2012, she won the British Thoracic Oncology Group International Award for Contributions to Lung Cancer Research, the Royal College of Physicians and Surgeons of Canada Whiteman Award and Visiting Professorship and a Queen Elizabeth II Diamond Jubilee medal and a Giants of Cancer Care Award for Lung Cancer in 2016. In 2015, she was appointed as an Officer of the Order of Canada, and most recently in 2018, she won a Gairdner-Wightman award.

David Small, MD, FRCPC

Associate Professor of Medicine
McGill University
Montreal, QC

Dr. David Small is an Associate Professor of Medicine at McGill University based at the Jewish General Hospital. He was Chief of the Division of Pulmonary Medicine at the Jewish General Hospital for approximately 15 years and stepped down 4 years ago. Dr. Small was instrumental in developing the Lung Cancer Program at the Jewish General Hospital and continues to play a very active role in all of the clinical and research activities, as well as in mentoring junior faculty.  

Paula A. Ugalde Figueroa, MD

Thoracic surgeon – Institut Universitaire de Cardiologie et de Pneumologie de Québec – Université Laval (IUCPQ – UL)
Associate Professor
Laval University – Quebec, CA

Doctor Ugalde graduated from Federal University of the Bahia, Brazil. She received a training in General Surgery and Thoracic Surgery at Santa Casa da Misericordia in Porto Alegre. Soon after, she completed a Master’s degree in Medicine and Health – Federal University of the Bahia (2004), Brazil.

To pursue her further training, she applied for an international two-year fellowship at the Quebec Heart and Lung Institute (Institut Universitaire de Cardiologie et de Pneumologie de Québec – Université Laval) and a one-year fellowship at the University of Pittsburgh Medical Center Heart, Lung and Esophageal Surgery Institute.
She is currently the research coordinator in Thoracic Oncology and Thoracic Surgeon at the Institut Universitaire de Cardiologie et de Pneumologie de Québec, Canada.

She is specialized in surgical management of lung cancer and esophageal cancer with a focus on minimally invasive thoracic surgery. As a researcher, she strikes for the development of technology and innovation at the Institut and supervises

Gregory M. M. Videtic, MDCM, FRCPC, FACR, FASTRO

Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Staff Physician, Department of Radiation Oncology
Cleveland Clinic’s Taussig Cancer Institute
Clevland, OH

Dr. Videtic is a Staff Physician in the Department of Radiation Oncology of the Cleveland Clinic’s Taussig Cancer Institute and a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

He was born in Montreal and attended McGill University where he obtained a B.Sc. with Honors in Physiology, followed by completion of his medical degree. He completed a Residency in Family Medicine at Dalhousie University in Halifax, Nova Scotia, in 1988. He completed a Fellowship in Geriatrics Research at the University of Western Ontario in 1992 then returned there for a Residency in Radiation Oncology, completing it in 1997. He completed a CNS Radiosurgery/Brachytherapy Fellowship in 1998 at Wayne State University in Detroit, MI, under the mentorship of Dr. Laurie Gaspar.

His first staff position was at the London Regional Cancer Centre in London, Ontario. He then moved to the Dana-Farber Cancer Institute, Boston, MA, in 2000, followed by a move to the Cleveland Clinic’s Department of Radiation Oncology in 2003. At the Clinic, he is currently the Director of Thoracic Radiation Oncology, with primary responsibility to leading the lung stereotactic body radiotherapy program since its inception in 2004.

Among other affiliations, he is a member of the Lung Cancer Steering Committee of the Radiation Therapy Oncology Group (RTOG) and was the Principal Investigator for RTOG 0915. He was Senior Editor (Thoracic) for the “International Journal of Radiation Oncology, Biology, Physics” from 2013 to 2016 and is an Executive Editor at “ASTRO’s Advances in Radiation Oncology” Journal since 2016.

Graham Warren M.D., Ph.D.

Professor
Vice Chairman for Research in Radiation Oncology
Department of Radiation Oncology
Department of Cell and Molecular Pharmacology and Experimental Therapeutics
Hollings Cancer Center
Medical University of South Carolina
South Carolina, USA

Graham Warren is a radiation oncologist and Vice Chairman for Research in Radiation Oncology at the Medical University of South Carolina with a primary interest in addressing the biologic, clinical, behavioral, and financial aspects of tobacco use by cancer patients.  He authored seminal sections of the Surgeon General’s Report on the adverse effects of smoking by cancer patients and works at the institutional, state, regional, and national level to address tobacco use by cancer.  He is an advisor for the Canadian Partnership Against Cancer (CPAC) supporting implementation of strategies to address tobacco use across Canada with the primary objective of improving the efficacy of cancer treatment.

John Yee, MD, FRCS(C)

Assistant Professor- Division of Thoracic Surgery, UBC
Director- Lung Transplant Program, VGH
Vancouver, BC

Dr. John Yee is an Assistant Professor-Division of Thoracic Surgery, UBC and Director- Lung Transplant Program, VGH.

Dr. Yee is a designate of the Chair of the UBC Department of Surgery for the Surgical Oncology Network Council Executive.

Kelly Zibrik, MScN, RN

Coordinator, Lung Tumor Group
BC Cancer
Vancouver, BC

Kelly Zibrik received her Bachelor in Science in Nursing degree from the University of British Columbia in 2002 and a Masters degree in Nursing from the University of Northern British Columbia in 2009. She has worked at  BC Cancer  since 2004 in various clinical nursing roles and is currently working as a nurse triage coordinator with the lung tumor group at the Vancouver Centre.